![](https://oxolife.com/wp-content/uploads/2020/11/4.7.2057373416_LaVanguardia_20191209_CAS_CAT-992x558@LaVanguardia-Web-702x526.jpg)
The biotechnology company Oxolife returns to its founders: Agnès Arbat and Ignasi Canals have regained the license of their product OXO-001, a patented drug for the treatment of infertility. They have recently opened a crowdfunding round through the Capital Cell platform to take the drug to phase 2.